Back to News
Market Impact: 0.2
Eli Lilly, Regeneron Lead Weight-Loss ETF THNR Higher
Source: etftrends.com
Corporate EarningsHealthcare & BiotechCompany Fundamentals
The Amplify Weight Loss Drug & Treatment ETF (THNR) returned 3.2% in October, according to Amplify ETFs. Eli Lilly drove most of the gain after reporting quarterly results that beat Wall Street forecasts.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
LLY0.70
More News
- Novo raises full-year outlook as Wegovy sales impress
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT